Chimeric Therapeutics Limited
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurre… Read more
Market Cap & Net Worth: Chimeric Therapeutics Limited (CHMMF)
Chimeric Therapeutics Limited (PINK:CHMMF) has a market capitalization of $4.42 Million ($4.42 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #33522 globally and #10945 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chimeric Therapeutics Limited's stock price $0.00 by its total outstanding shares 4418703619 (4.42 Billion).
Chimeric Therapeutics Limited Market Cap History: 2022 to 2025
Chimeric Therapeutics Limited's market capitalization history from 2022 to 2025. Data shows change from $265.12 Million to $4.42 Million (-83.14% CAGR).
Chimeric Therapeutics Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chimeric Therapeutics Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.11x
Chimeric Therapeutics Limited's market cap is 1.11 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $265.12 Million | $2.62 Million | -$15.90 Million | 101.30x | N/A |
| 2023 | $132.56 Million | $4.51 Million | -$25.50 Million | 29.42x | N/A |
| 2025 | $4.42 Million | $3.97 Million | -$10.43 Million | 1.11x | N/A |
Competitor Companies of CHMMF by Market Capitalization
Companies near Chimeric Therapeutics Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Chimeric Therapeutics Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Chimeric Therapeutics Limited Historical Marketcap From 2022 to 2025
Between 2022 and today, Chimeric Therapeutics Limited's market cap moved from $265.12 Million to $ 4.42 Million, with a yearly change of -83.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.42 Million | 0.00% |
| 2024 | $4.42 Million | -96.67% |
| 2023 | $132.56 Million | -50.00% |
| 2022 | $265.12 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Chimeric Therapeutics Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.42 Million USD |
| MoneyControl | $4.42 Million USD |
| MarketWatch | $4.42 Million USD |
| marketcap.company | $4.42 Million USD |
| Reuters | $4.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.